• Quercetin, Hippo Signaling, and Cataract Protection

  2026-10-08

  A 2025 study links quercetin’s protective effects in cataract models to suppression of Hippo pathway activity, reduced oxidative stress, and improved lens epithelial-cell survival. The evidence is mechanistically suggestive but remains limited to network analysis, mouse models, and injured cell cultures, so its clinical relevance requires further validation.

• Veratridine: From Channel Gating to Translation

  2026-10-08

  A source-grounded perspective on Veratridine as a voltage-gated sodium channel opener, integrating sodium channel dynamics research, excitotoxicity studies, assay strategy, translational limits, and future opportunities.

• Locally Produced DENV-1 RT-LAMP: Study Insights

  2026-10-07

  The 2025 reference study presents a modular recombinant enzyme system and a DENV-1 primer design intended to reduce dependence on imported diagnostic ingredients in resource-limited settings. Its reported analytical evidence includes detection at 10 copies and discrimination of positive and negative reactions through turbidity, but the work remains pre-clinical and does not establish clinical diagnostic performance.

• Glabridin–Gold(I) Complex and Antitumor Immunity

  2026-10-07

  The reference study introduces complex 6d, which combines an N-heterocyclic carbene gold(I) center with glabridin to target both thioredoxin reductase and MAPK-related immunosuppressive signaling. In liver cancer models, the authors report enhanced dendritic-cell maturation, reduced suppressive immune-cell populations, lower PD-L1 expression, and increased granzyme B, while emphasizing that further validation is needed before clinical translation.

• BH3-Mimetics and Apoptotic Sensitivity in Glioblastoma

  2026-10-06

  Koessinger and colleagues found that glioblastoma, including stem-like tumor cells, depends on the anti-apoptotic proteins BCL-xL and MCL-1 and displays increased apoptotic priming. Their study supports a context-dependent strategy in which combined targeting of these survival dependencies produces antitumor activity in preclinical models, while also highlighting the limits of translating findings from GBM models to clinical treatment.

• From Multiplexed CRISPR to Translational Evidence

  2026-10-06

  Multiplexed CRISPR can generate richer biological insight than single-target editing, but its translational value depends on evidence quality, cellular context, and control of unintended structural and stress responses. This thought-leadership article explains how 293T Cells can support early, human-cell feasibility assessments without being mistaken for a disease-relevant or clinical surrogate.

• ARB Reprogramming of Armored and Cold Tumors

  2026-10-05

  Mei et al. identify AGTR1, the target of angiotensin receptor blockers, as a vulnerability in collagen-rich, immune-excluded armored and cold tumors. Their transcriptomic, mechanistic, in vivo, cohort, and meta-analytic evidence supports a model in which ARB-associated suppression of CAF collagen production may improve response to immune checkpoint blockade, while leaving important questions about causality and clinical translation.

• GDC-0941: PI3K Inhibition and Evidence Boundaries

  2026-10-05

  GDC-0941 is a reported PI3K inhibitor with preferential biochemical activity against PI3Kα and PI3Kδ. Its relevance to PI3K/Akt pathway inhibition in liver cancer is mechanistically plausible but remains distinct from direct evidence in the DRD4-driven hepatocellular carcinoma model.

• Dimetridazole: From Virulence Biology to Translation

  2026-10-04

  Dimetridazole is emerging as a research probe for studying quorum sensing, virulence attenuation, and antibiotic potentiation in Pseudomonas aeruginosa. This evidence-led analysis separates reported findings from translational hypotheses and outlines the questions researchers should resolve before treating antivirulence activity as a development opportunity.

• Dual Enzyme-Responsive Peptides for Cancer Selectivity

  2026-10-03

  A 2026 Biomacromolecules study reports a zwitterionic peptide amphiphile that uses sequential matrix metalloproteinase-7 and cathepsin B responses to control intracellular self-assembly. The design achieved a reported cancer selectivity index of 64.1 and tumor regression in an HT-29 xenograft model, while the available evidence remains limited to defined experimental systems rather than clinical application.

• Nelfinavir Mesylate at the HIV–Ferroptosis Interface

  2026-10-02

  Nelfinavir Mesylate is best known as an orally bioavailable HIV-1 protease inhibitor, but recent evidence positions it as a useful pharmacological bridge between viral maturation, DDI2–NFE2L1 proteostasis, and ferroptosis research. This article explains how to validate target engagement, separate antiviral from proteostasis-driven effects, and translate the compound responsibly across research domains.

• Fasudil (HA-1077) HCl ROCK Workflows

  2026-10-01

  Build reproducible ROCK inhibition experiments for proliferation, migration, and apoptosis studies with a practical Fasudil workflow. The guide also shows how recent Hippo-pathway cataract research can improve assay controls without implying an unvalidated ROCK–Hippo mechanism.

• Fluorescein Tyramide: From Signal to Spatial Biology

  2026-10-01

  Fluorescein Tyramide extends tyramide signal amplification from routine staining to spatially resolved neuroscience. This article translates recent oxytocin-circuit findings into practical decisions for IHC, ISH, and quantitative tissue imaging.

• Veratridine: A Causal Map of Excitotoxicity

  2026-09-30

  Veratridine is a voltage-gated sodium channel opener that reveals how persistent depolarization becomes excitotoxic injury. This article translates landmark cortical-culture findings into a practical framework for sodium channel dynamics research and blocker-screening assay design.

• AGTR1 Blockade Reprograms Cold Tumors for ICB

  2026-09-30

  The reference study identifies AGTR1 as a stromal therapeutic target in collagen-rich, immune-excluded tumors and shows that angiotensin receptor blockade can remodel the tumor microenvironment to improve immune checkpoint blockade. Its main contribution is linking cancer-associated fibroblast signaling, collagen deposition, and clinical medication-use data in a unified framework.

8226 records 1/549 page Next 12345 下5页 Last page